New guidelines overhaul best practices for heart failure prevention, diagnosis and treatment

Updated heart failure management guidelines add recommendations for the use of SGLT inhibitors and for managing patients with cancer therapy-related cardiotoxicity.

2:00 PM

Author | Haley Otman

heart image lab note navy blue yellow
Michigan Medicine

Clinicians now have an up-to-date, data-driven destination to help them provide the best care possible to their patients with heart failure, thanks to the publication of new clinical practice guidelines from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America.

The new guidelines provide a tremendous resource for physicians who are looking for the latest data to help them care for their patients, given that the last full guideline was published nearly 10 years ago, says Salim Hayek, M.D., an assistant professor of internal medicine and a cardiologist at the University of Michigan Health Frankel Cardiovascular Center, who served on the writing committee.

Physicians who care for patients with heart failure with and without reduced ejection fraction will find new recommendations regarding sodium-glucose cotransporter-2, or SGLT, inhibitors in the guideline.

"This class of drugs, initially meant for treating diabetes, have been shown to be amazing therapies for patients with heart failure," Hayek said. "Most importantly, they work well in patients with heart failure and preserved ejection fraction, a group of patients for which effective treatments are lacking."

Another key message is that heart failure specialty teams, like the Frankel CVC offers, are key to evaluating patients with advanced heart failure and providing life-saving therapies, added guideline writing committee member Monica Colvin, M.D., M.S., associate director of the heart transplant program and an advanced heart failure and transplant cardiologist at the Frankel CVC.

Reducing the prevalence of heart failure to begin with is also given great importance: The heart failure stages are revised to emphasize prevention for people at risk of heart failure or who have pre-heart failure.

In addition, economic analyses are included for some treatments, with value statements to help clinicians and patients who are determining whether to try something expensive. Only one therapy was defined as low-value: tafamidis for cardiac amyloidosis.

And for the first time, the guideline offers recommendations for cardio-oncology, a clinical focus for Hayek, providing guidance on the management and prevention of cancer-therapy related cardiotoxicity.

It's important to note the patient-centric approach of the new guideline, Hayek and Colvin added.

Guideline cited: "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint 4 Committee on Clinical Practice Guidelines."

More Articles About: Lab Notes Heart Failure Cardiovascular: Preventive Cardiology Cardiovascular: Diseases & Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories supar molecule teal blue yellow red
Health Lab
Immune protein suPAR links viral infection as possible cause of kidney disease
Through a series of experiments in non-human primates, mice and humans, a multi-institutional team led by researchers from Michigan Medicine and Rush University found that the immune protein soluble urokinase plasminogen activator receptor, or suPAR, is an important link between viral infections and proteinuria; the elevation of protein in the urine is known to cause glomerulopathy, a common form of kidney disease.
heart organ yellow blue
Health Lab
Irregular heartbeat after valve surgery increases risk of stroke, death
Postoperative atrial fibrillation, commonly known as Afib, has traditionally been viewed as benign and limited. But a study led by researchers at the University of Michigan Health Frankel Cardiovascular Center finds that postoperative atrial fibrillation increases the risk of strokes and permanent Afib — and is linked to worse long term survival — after heart valve surgery.
human organ for transplant
Health Lab
Findings shed light on how a pediatric heart surgery complication impacts heart transplant survival
Patients who experience this condition following the Fontan continue to have a high risk of death from the time they’re waitlisted for a new heart through receiving the transplant, according to a 20-center study led by Michigan Medicine. And one specific complication called cyanosis – or experiencing less than normal oxygen blood levels – was associated with worsened survival.
Brain image highlighting areas
Health Lab
Women stroke survivors believe they will receive worse care in the emergency room
National study examined health care perceptions of approximately 3,500 women, including those with and without a history of stroke
surgeons in OR with blue and teal scrubs with screen on and patient under teal sheet
Health Lab
Treating heart valve disease: What are your options?
Michigan Medicine’s head of cardiac surgery, Gorav Ailawadi, M.D, M.B.A., answers questions about different treatment options for heart valve disease.
red lines with heart through it beige background
Health Lab
Research finds potential target for cardiovascular disease in diabetes
University of Michigan researchers found that the overproduction of neutrophil extracellular traps is an important contributing factor to vascular dysfunction in diabetes.